Mirtazapina Krka (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Krka, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapina Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant sourcing for global markets. Clients benefit from reliable logistics, batch traceability, and responsive technical support.

Mirtazapine is used primarily in the management of depressive disorders, acting on noradrenergic and serotonergic pathways. - Major depressive disorder: alleviates depressive symptoms and improves mood. - Depression‑related anxiety: reduces anxiety symptoms accompanying depression. - Depression‑associated insomnia: improves sleep quality in patients with depressive insomnia.

Mirtazapine may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Sedation or drowsiness. - Increased appetite and weight gain. - Dry mouth. - Constipation.

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction or elevated liver enzymes. - Suicidal thoughts or behavior, especially early in treatment.

Before initiating therapy, clinicians should consider several safety measures. - Assess hepatic function: evaluate liver enzymes prior to treatment. - Monitor weight: track changes due to increased appetite. - Screen for suicidal ideation: especially during the first weeks. - Avoid abrupt discontinuation: taper the dose under medical supervision. - Store at ambient temperature: keep in the original pack, protect from moisture.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - CNS depressants (alcohol, benzodiazepines): enhanced sedation. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine): increased mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - Other serotonergic agents (SSRIs, SNRIs): potential serotonin syndrome. - Antihistamines: additive sedative effect. - Warfarin: possible alteration of INR and bleeding risk.